Available since November 2019, EGRIFTA SV™ has the following key features versus
Lower injection volume (0.35 mL vs 2 mL);
Room temperature storage (between 68°F to 77°F).
Given the commercial availability of EGRIFTA SV™ since November 2019 and its key
features, EGRIFTA® will no longer be manufactured as of June 15ᵗʰ, 2020.
Most patients have been successfully transitioned to EGRIFTA SV™, if you are
still receiving EGRIFTA® you can contact your healthcare provider or THERA
patient support® (at 1-833-23THERA or 1-833-238-4372, Mon-Fri 8:30AM-8:00PM ET)
to understand your options.
The full Prescribing Information, Patient Information, and Instructions for Use for EGRIFTA SV™
can be found on www.egriftasv.com.
The full Prescribing Information, Patient Information, and Instructions for Use for EGRIFTA®
can be found on www.egrifta.com.
Important information regarding and COVID-19 Pandemic.
Our primary objective at Theratechnologies is to ensure the
health of Persons with HIV and the continuity of care for any patient in need of
EGRIFTA® during the COVID-19 period. We are here to
assist you and your team in any way that we can.
For current EGRIFTA®
patients, we are fully prepared to support them in light of the COVID-19 situation.
Should you have any question related to EGRIFTA®, we are here to help through THERA
® (1-833-238-4372, Mon-Fri 8:30AM-8:00PM ET). We provide support in the
form of injection training, insurance coverage analysis and co-pay assistance.
Rest assured that we presently have enough inventory, here in
the U.S., for all currently prescribed EGRIFTA®
patients during the next 12 months. In addition, the production is not affected
for EGRIFTA® at this stage by the COVID-19 situation.
The full Prescribing Information and Important Safety Information about
EGRIFTA® are available here.